Dongwha Pharm

KSC:000020 · KR7000020008

PharmaceuticalsSmall

360

Medium confidence — indicative

Value55

Profit price94

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price86

Price/Sales86

EV / Gross Profit83

Price/Book89

Quality51

Returns on capital67

Return on Capital70

Cash Return on Capital59

Return on Equity71

Profit margins71

EBIT Margin60

Gross Profitability81

Cash backing34

Cash Conversion25

Accruals19

Owner Earnings Margin57

Growth57

Sales growth38

Profit growth84

Profit Growth100

Long-Term EPS Growth67

Reinvestment32

Price momentum50

Safety29

Debt load62

Debt serviceability42

Refinancing82

Debt Payback1

Liquidity32

Sentiment50

Analyst ratings—

Expectations trend—

Market mood63

Value Creation6/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Dongwha Pharm doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeKOSE

Employees27

Websitedong-wha.co.kr

ISINKR7000020008

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

Pain ManagementCardiovascularDermatologyRespiratoryCentral Nervous SystemManufacturingMedicalPharmaceutical

Description

Analysis

Middle-of-the-road

Dongwha Pharm.Co.,Ltd sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 6/20 on our value-creation score: not creating value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Dongwha Pharm with its peers

Kukje Pharma

KSC:002720

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Ildong Holdings

KSC:000230

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Ilsung IS

KSC:003120

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

PharmGen Science

KSC:004720

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Samsung Pharm

KSC:001360

—

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Whanin Pharm

KSC:016580

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →